SWHR Submits Letter to ICER on Draft Scoping Document for Fezolinetant
SWHR sent a letter to the Institute for Clinical and Economic Review (ICER) over its draft scoping document related to its upcoming assessment of fezolinetant for moderate to severe vasomotor symptoms (VMS) associated with menopause. SWHR’s letter shared points for ICER’s consideration related to the availability of current and necessary VMS treatment options and the quality of life for women dealing with VMS.
SWHR sent a letter to the Institute for Clinical and Economic Review (ICER) over its draft scoping document related to its upcoming assessment of fezolinetant for moderate to severe vasomotor symptoms (VMS) associated with menopause. SWHR’s letter shared points for ICER’s consideration related to the availability of current and necessary VMS treatment options and the quality of life for women dealing with VMS.